MedTrace Logo

Yorkshire Kidney Screening Trial

NCT05005195 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5850

Last updated 2022-11-02

No results posted yet for this study

Summary

Kidney cancer is the 8th most common cancer in Yorkshire. It has a poor survival rate, with only 6 out of 10 patients diagnosed with kidney cancer still alive after 5 years. This is partly because many people with kidney cancer don't have any symptoms. In some of these people, kidney cancer is only found by chance during investigations for other reasons. In others, it is often not diagnosed until the disease has passed the point at which we can easily cure it.

Screening for kidney cancer has the potential to pick up these cancers earlier and increase the number of people who can be cured. The Yorkshire Lung Screening Trial offers people aged 55-80 with a history of smoking a CT scan as part of a lung health check. This group of people is also at increased risk of developing kidney cancer. Our new study, the Yorkshire Kidney Screening Trial, will piggyback on this trial to offer an extra CT scan for kidney cancer. The extra scan will take 10 seconds. By the end of the study we will understand whether it is workable to roll this out more widely and whether people take up this extra scan.

Conditions

Interventions

RADIATION

Low dose abdominal computed tomography scan

A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer

Sponsors & Collaborators

  • University of Cambridge

    collaborator OTHER

  • Yorkshire Cancer Research

    collaborator OTHER

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • University of Leeds

    lead OTHER

Principal Investigators

  • Grant D Stewart · University of Cambridge

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05005195 on ClinicalTrials.gov